DexCom price target lowered to $80 from $98 at Barclays

Barclays lowered the firm’s price target on DexCom (DXCM) to $80 from $98 and keeps an Equal Weight rating on the shares. The company reported an earnings and sales beat, but management’s guide down of margins due to scrap related to its increased quality initiatives and tempered initial thoughts on 2026 will bring near-term pressure on the shares, the analyst tells investors in a research note.